A Review of Diabetes Treatment Adherence and the Association with Clinical and Economic Outcomes

Clinical Therapeutics

Volumn 33, Issue 1, 2011, Pages 74-109

  Asche, Carl ^a   LaFleur, Joanne ^a   Conner, Chris ^b  

^a UNIVERSITY OF UTAH   (United States)

^b NOVO NORDISK INC   (United States)

Author keywords

Diabetes mellitus; Glycemic control; Hypoglycemic agents; Insulin; Medication adherence

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; EXENDIN 4; GLIPIZIDE; INSULIN; METFORMIN; PIOGLITAZONE; SITAGLIPTIN;

ARTICLE; DATA EXTRACTION; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; ECONOMIC EVALUATION; GLYCEMIC CONTROL; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MEDLINE; MORTALITY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PSYCHOLOGY; QUALITY OF LIFE;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HEALTH CARE COSTS; HEALTH SERVICES; HUMANS; HYPOGLYCEMIC AGENTS; MEDICATION ADHERENCE; QUALITY OF LIFE;

EID: 79952498421     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.01.019     Document Type: Article

References (67)

1. IDF Diabetes Atlas: Mobidity and mortality International Diabetes Federation, Accessed 7 May 2010. http://www.diabetesatlas.org/content/diabetes-mortality.
2. 2007 National Diabetes Statistics. National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) National Diabetes Information Clearinghouse (NDIC), Updated June 2008. Accessed 31 August 2009. http://diabetes.niddk.nih.gov/DM/PUBS/statistics/%23what.
3. Narayan K.M., Boyle J.P., Geiss L.S., et al. Impact of recent increase in incidence on future diabetes burden: U.S., 2005-2050. Diabetes Care 2006, 29:2114-2116.
4. Nathan D.M., Buse J.B., Davidson M.B., et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203.
5. Cramer J.A. A systematic review of adherence with medications for diabetes. Diabetes Care 2004, 27:1218-1224.
6. Cramer J.A., Roy A., Burrell A., et al. Medication compliance and persistence: Terminology and definitions. Value Health 2008, 11:44-47.
7. Lewis A. Noncompliance: A $100 billion problem. Remington Rep 1997, 5:14-15.
8. Abdelghaffar S., Attia A.M. Metformin added to insulin therapy for type 1 diabetes mellitus in adolescents. Cochrane Database Syst Rev 2009, CD006691.
9. Vardi M., Jacobson E., Nini A., Bitterman H. Intermediate acting versus long acting insulin for type 1 diabetes mellitus. Cochrane Database Syst Rev 2008, CD006297.
10. Richter B., Bandeira-Echtler E., Bergerhoff K., et al. Rosiglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007, CD006063.
11. Black C., Donnelly P., McIntyre L., et al. Meglitinide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007, CD004654.
12. Richter B., Bandeira-Echtler E., Bergerhoff K., et al. Pioglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev 2006, CD006060.
13. Saenz A., Fernandez-Esteban I., Mataix A., et al. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005, CD002966.
14. Fineman M.S., Bicsak T.A., Shen L.Z., et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003, 26:2370-2377.
15. Buse J.B., Henry R.R., Han J., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004, 27:2628-2635.
16. Kendall D.M., Riddle M.C., Rosenstock J., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005, 28:1083-1091.
17. DeFronzo R.A., Ratner R.E., Han J., et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28:1092-1100.
18. Heine R.J., Van Gaal L.F., Johns D., et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: A randomized trial. Ann Intern Med 2005, 143:559-569.
19. Riddle M.C., Henry R.R., Poon T.H., et al. Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabetes Metab Res Rev 2006, 22:483-491.
20. Ratner R.E., Maggs D., Nielsen L.L., et al. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab 2006, 8:419-428.
21. Blonde L., Klein E.J., Han J., et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006, 8:436-447.
22. Kim D., MacConell L., Zhuang D., et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007, 30:1487-1493.
23. Zinman B., Hoogwerf B.J., Duran Garcia S., et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: A randomized trial. Ann Intern Med 2007, 146:477-485.
24. Campbell R.K. Glimepiride: Role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. Ann Pharmacother 1998, 32:1044-1052.
25. Secnik Boye K., Matza L.S., Oglesby A., et al. Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes. Health Qual Life Outcomes 2006, 4:80.
26. Salas M., Hughes D., Zuluaga A., et al. Costs of medication nonadherence in patients with diabetes mellitus: A systematic review and critical analysis of the literature. Value Health 2009, 12:915-922.
27. Adams A.S., Trinacty C.M., Zhang F., et al. Medication adherence and racial differences in A1C control. Diabetes Care 2008, 31:916-921.
28. Alvarez Guisasola F., Tofe Povedano S., Krishnarajah G., et al. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: Findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. Diabetes Obes Metab 2008, 10(Suppl 1):25-32.
29. Balkrishnan R., Arondekar B.V., Camacho F.T., et al. Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in Medicaid-enrolled patients with type 2 diabetes mellitus. Clin Ther 2007, 29(Spec No):1306-1315.
30. Balkrishnan R., Rajagopalan R., Camacho F.T., et al. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: A longitudinal cohort study. Clin Ther 2003, 25:2958-2971.
31. Blonde L., Wogen J., Kreilick C., Seymour A.A. Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administered with metformin. Diabetes Obes Metab 2003, 5:424-431.
32. Colombi A.M., Yu-Isenberg K., Priest J. The effects of health plan copayments on adherence to oral diabetes medication and health resource utilization. J Occup Environ Med 2008, 50:535-541.
33. Cox D.J., Taylor A.G., Nowacek G., et al. The relationship between psychological stress and insulin-dependent diabetic blood glucose control: Preliminary investigations. Health Psychol 1984, 3:63-75.
34. Donnelly L.A., Morris A.D., Evans J.M. Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes. QJM 2007, 100:345-350.
35. Evans J.M., Donnan P.T., Morris A.D. Adherence to oral hypoglycaemic agents prior to insulin therapy in Type 2 diabetes. Diabet Med 2002, 19:685-688.
36. Glasgow R.E., McCaul K.D., Schafer L.C. Self-care behaviors and glycemic control in type I diabetes. J Chronic Dis 1987, 40:399-412.
37. Grant R., Adams A.S., Trinacty C.M., et al. Relationship between patient medication adherence and subsequent clinical inertia in type 2 diabetes glycemic management. Diabetes Care 2007, 30:807-812.
38. Guillausseau P.J. Influence of oral antidiabetic drugs compliance on metabolic control in type 2 diabetes. A survey in general practice. Diabetes Metab 2003, 29:79-81.
39. Heisler M., Faul J.D., Hayward R.A., et al. Mechanisms for racial and ethnic disparities in glycemic control in middle-aged and older Americans in the health and retirement study. Arch Intern Med 2007, 167:1853-1860.
40. Hepke K.L., Martus M.T., Share D.A. Costs and utilization associated with pharmaceutical adherence in a diabetic population. Am J Manag Care 2004, 10:144-151.
41. Horswell R.L., Wascom C.K., Cerise F.P., et al. Diabetes mellitus medication assistance program: Relationship of effectiveness to adherence. J Health Care Poor Underserved 2008, 19:677-686.
42. Johnson S.B., Freund A., Silverstein J., et al. Adherence-health status relationships in childhood diabetes. Health Psychol 1990, 9:606-631.
43. Johnson S.B., Kelly M., Henretta J.C., et al. A longitudinal analysis of adherence and health status in childhood diabetes. J Pediatr Psychol 1992, 17:537-553.
44. Karve S., Cleves M.A., Helm M., et al. An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients. Med Care 2008, 46:1125-1133.
45. Kindmalm L., Melander A., Nilsson J.L. Refill adherence of antihyperglycaemic drugs related to glucose control (HbA1c) in patients with type 2 diabetes. Acta Diabetol 2007, 44:209-213.
46. Kleinman N.L., Schaneman J.L., Lynch W.D. The association of insulin medication possession ratio, use of insulin glargine, and health benefit costs in employees and spouses with type 2 diabetes. J Occup Environ Med 2008, 50:1386-1393.
47. Kogut S.J., Andrade S.E., Willey C., Larrat E.P. Nonadherence as a predictor of antidiabetic drug therapy intensification (augmentation). Pharmacoepidemiol Drug Saf 2004, 13:591-598.
48. Krapek K., King K., Warren S.S., et al. Medication adherence and associated hemoglobin A1c in type 2 diabetes. Ann Pharmacother 2004, 38:1357-1362.
49. Kuo Y.F., Raji M.A., Markides K.S., et al. Inconsistent use of diabetes medications, diabetes complications, and mortality in older Mexican Americans over a 7-year period: Data from the Hispanic established population for the epidemiologic study of the elderly. Diabetes Care 2003, 26:3054-3060.
50. Lau D.T., Nau D.P. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care 2004, 27:2149-2153.
51. Lawrence D.B., Ragucci K.R., Long L.B., et al. Relationship of oral antihyperglycemic (sulfonylurea or metformin) medication adherence and hemoglobin A1c goal attainment for HMO patients enrolled in a diabetes disease management program. J Manag Care Pharm 2006, 12:466-471.
52. Lewin A.B., Heidgerken A.D., Geffken G.R., et al. The relation between family factors and metabolic control: The role of diabetes adherence. J Pediatr Psychol 2006, 31:174-183.
53. Martinez Y.V., Prado-Aguilar C.A., Rascon-Pacheco R.A., Valdivia-Martinez J.J. Quality of life associated with treatment adherence in patients with type 2 diabetes: A cross-sectional study. BMC Health Serv Res 2008, 8:164.
54. Morris A.D., Boyle D.I., McMahon A.D., et al. Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus. Diabetes Audit and Research in Tayside Scotland. Medicines Monitoring Unit. Lancet 1997, 350:1505-1510. The DARTS/MEMO Collaboration.
55. Murata G.H., Duckworth W.C., Shah J.H., et al. Sources of glucose variability in insulin-treated type 2 diabetes: The Diabetes Outcomes in Veterans Study (DOVES). Clin Endocrinol (Oxf) 2004, 60:451-456.
56. Parchman M.L., Pugh J.A., Wang C.P., Romero R.L. Glucose control, self-care behaviors, and the presence of the chronic care model in primary care clinics. Diabetes Care 2007, 30:2849-2854.
57. Piette J.D., Wagner T.H., Potter M.B., Schillinger D. Health insurance status, cost-related medication underuse, and outcomes among diabetes patients in three systems of care. Med Care 2004, 42:102-109.
58. Pladevall M., Williams L.K., Potts L.A., et al. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care 2004, 27:2800-2805.
59. Rhee M.K., Slocum W., Ziemer D.C., et al. Patient adherence improves glycemic control. Diabetes Educ 2005, 31:240-250.
60. Rothman R.L., Mulvaney S., Elasy T.A., et al. Self-management behaviors, racial disparities, and glycemic control among adolescents with type 2 diabetes. Pediatrics 2008, 121:e912-e919.
61. Rozenfeld Y., Hunt J.S., Plauschinat C., Wong K.S. Oral antidiabetic medication adherence and glycemic control in managed care. Am J Manag Care 2008, 14:71-75.
62. Shenolikar R.A., Balkrishnan R., Camacho F.T., et al. Comparison of medication adherence and associated health care costs after introduction of pioglitazone treatment in African Americans versus all other races in patients with type 2 diabetes mellitus: A retrospective data analysis. Clin Ther 2006, 28:1199-1207.
63. Sokol M.C., McGuigan K.A., Verbrugge R.R., Epstein R.S. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005, 43:521-530.
64. Gore M.O., McGuire D.K. The 10-year post-trial follow-up of the United Kingdom Prospective Diabetes Study (UKPDS): Cardiovascular observations in context. Diab Vasc Dis Res 2009, 6:53-55.
65. Brookhart M.A., Patrick A.R., Dormuth C., et al. Adherence to lipid-lowering therapy and the use of preventive health services: An investigation of the healthy user effect. Am J Epidemiol 2007, 166:348-354.
66. Palmer A.J., Roze S., Valentine W.J., et al. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004, 20(Suppl 1):S5-S26.
67. Palmer A.J., Roze S., Valentine W.J., et al. Validation of the CORE diabetes model against epidemiological and clinical studies. Curr Med Res Opin 2004, 20(Suppl 1):S27-S40.